Truist Financial Sticks to Their Hold Rating for Quest Diagnostics (DGX)
Analysts Offer Insights on Healthcare Companies: Altimmune (ALT), Quest Diagnostics (DGX) and BioNano Genomics (BNGO)
Mizuho Securities Sticks to Their Buy Rating for Quest Diagnostics (DGX)
Wells Fargo Adjusts Quest Diagnostics' Price Target to $140 From $135, Maintains Equal Weight Rating
No Data
No Data